DE69328622T2 - Reagenzien und verfahren zum nachweis und zur quantifizierung von thyroxin in flüssigen proben - Google Patents

Reagenzien und verfahren zum nachweis und zur quantifizierung von thyroxin in flüssigen proben

Info

Publication number
DE69328622T2
DE69328622T2 DE69328622T DE69328622T DE69328622T2 DE 69328622 T2 DE69328622 T2 DE 69328622T2 DE 69328622 T DE69328622 T DE 69328622T DE 69328622 T DE69328622 T DE 69328622T DE 69328622 T2 DE69328622 T2 DE 69328622T2
Authority
DE
Germany
Prior art keywords
thyroxin
quantifying
reagents
detecting
liquid samples
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69328622T
Other languages
English (en)
Other versions
DE69328622D1 (de
Inventor
Maciej Adamczyk
D Johnson
G Mattingly
E Clarisse
D Tyner
M Perkowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/859,775 external-priority patent/US5352803A/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of DE69328622D1 publication Critical patent/DE69328622D1/de
Publication of DE69328622T2 publication Critical patent/DE69328622T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y10S436/817—Steroids or hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE69328622T 1992-03-30 1993-03-29 Reagenzien und verfahren zum nachweis und zur quantifizierung von thyroxin in flüssigen proben Expired - Lifetime DE69328622T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/859,775 US5352803A (en) 1992-03-30 1992-03-30 5(6)-methyl substituted fluorescein derivatives
US07/973,140 US5359093A (en) 1992-03-30 1992-11-06 Reagents and methods for the detection and quantification of thyroxine in fluid samples
PCT/US1993/002909 WO1993020442A1 (en) 1992-03-30 1993-03-29 Reagents and methods for the detection and quantification of thyroxine in fluid samples

Publications (2)

Publication Number Publication Date
DE69328622D1 DE69328622D1 (de) 2000-06-15
DE69328622T2 true DE69328622T2 (de) 2001-02-08

Family

ID=27127537

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69328622T Expired - Lifetime DE69328622T2 (de) 1992-03-30 1993-03-29 Reagenzien und verfahren zum nachweis und zur quantifizierung von thyroxin in flüssigen proben
DE69332988T Expired - Lifetime DE69332988T2 (de) 1992-03-30 1993-03-29 Reagenzien zum Nachweis und zur Quantifizierung von Thyroxin in flüssigen Proben

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69332988T Expired - Lifetime DE69332988T2 (de) 1992-03-30 1993-03-29 Reagenzien zum Nachweis und zur Quantifizierung von Thyroxin in flüssigen Proben

Country Status (8)

Country Link
US (2) US5593896A (de)
EP (1) EP0649533B1 (de)
JP (1) JP3327551B2 (de)
CA (1) CA2131727A1 (de)
DE (2) DE69328622T2 (de)
ES (2) ES2198823T3 (de)
HK (1) HK1026264A1 (de)
WO (1) WO1993020442A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7981420B2 (en) 2000-12-22 2011-07-19 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)
EP1928905B1 (de) * 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
WO2007111851A1 (en) * 2006-03-24 2007-10-04 Aokin Ag Use of additives to lower the rate of a binding reaction
US20080102535A1 (en) * 2006-11-01 2008-05-01 Chace Donald H Measuring thyroxine levels from dried blood samples using mass spectrometry
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
US20090286329A1 (en) * 2008-05-19 2009-11-19 Abbott Laboratoires Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides
US20090286256A1 (en) * 2008-05-19 2009-11-19 Abbott Laboratories Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides
KR20110016959A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
EP3002299A1 (de) 2008-06-03 2016-04-06 AbbVie Inc. Dual-variable- domain-immunglobuline und ihre verwendungen
US8349325B2 (en) 2008-12-23 2013-01-08 Abbott Laboratories Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
RU2015132478A (ru) 2009-03-05 2015-12-10 Эббви Инк. Связывающие il-17 белки
EP2473852B1 (de) * 2009-08-31 2016-03-30 Abbott Laboratories Biomarker zur vorhersage von schweren unerwünschten kardialen ereignissen und ihre verwendung
CN113717286A (zh) * 2009-12-08 2021-11-30 Abbvie德国有限责任两合公司 用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
US20110229921A1 (en) 2010-03-18 2011-09-22 Abbott Laboratories METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS
JP5786020B2 (ja) 2010-04-16 2015-09-30 アボットジャパン株式会社 関節リウマチを診断する方法および試薬
BR122014011544A2 (pt) 2010-05-14 2019-08-13 Abbvie Inc proteínas de ligação à il-1
US9551714B2 (en) 2010-06-25 2017-01-24 Abbott Laboratories Materials and methods for assay of anti-hepatitis C virus (HCV) antibodies
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
MY160445A (en) 2010-08-03 2017-03-15 Abbvie Inc Dual Variable Domain Immunoglobulins And Uses Thereof
JP5713602B2 (ja) * 2010-08-20 2015-05-07 富士フイルム株式会社 チロキシンとアルブミンとの結合体を製造する方法
US20120115244A1 (en) 2010-11-09 2012-05-10 Abbott Laboratories Materials and methods for immunoassay of pterins
BR112013015944A2 (pt) 2010-12-21 2018-06-19 Abbvie Inc imunoglobulinas de domínio duplo variável il-1 alpha e beta biespecífico e seus usos.
CN104203978A (zh) 2011-10-24 2014-12-10 艾伯维股份有限公司 针对硬化蛋白的免疫结合剂
MX2014004980A (es) 2011-10-24 2014-09-11 Abbvie Inc Inmunoaglutinantes biespecificos dirigidos contra tnf e il-17.
EP2791173B1 (de) 2011-12-14 2020-07-29 AbbVie Deutschland GmbH & Co. KG Zusammensetzung und verfahren zur diagnose und behandlung von durch eisenmangel bedingten erkrankungen
US9636398B2 (en) 2011-12-14 2017-05-02 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
US8993248B2 (en) 2011-12-31 2015-03-31 Abbott Laboratories Truncated human vitamin D binding protein and mutation and fusion thereof and related materials and methods of use
LT2807192T (lt) 2012-01-27 2018-07-25 AbbVie Deutschland GmbH & Co. KG Kompozicijos ir būdai, skirti ligų, susijusių su neuritų degeneracija, diagnostikai ir gydymui
KR20140147837A (ko) 2012-03-13 2014-12-30 애브비 인코포레이티드 Ｖ1ｂ 길항제 치료요법을 위한 대상체를 선택하거나 선별하는 방법
AR091755A1 (es) 2012-07-12 2015-02-25 Abbvie Inc Proteinas de union a il-1
DE112013006579T5 (de) 2013-02-02 2016-03-10 Duke University Verfahren zum Isolieren zirkulierender Tumorzellen
JP6739329B2 (ja) 2013-03-14 2020-08-12 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ Ｈｃｖコア脂質結合ドメインモノクローナル抗体
WO2014143342A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
BR112015023239A8 (pt) 2013-03-14 2018-04-17 Abbott Lab ensaio de combinação de anticorpo-antígeno de hcv e métodos e composições para uso do mesmo
US9157910B2 (en) 2013-03-15 2015-10-13 Abbott Laboratories Assay with increased dynamic range
US9005901B2 (en) 2013-03-15 2015-04-14 Abbott Laboratories Assay with internal calibration
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
WO2015031626A1 (en) 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
BR112016030008A2 (pt) 2014-06-27 2017-10-24 Abbott Lab método para a detecção de infecção por pegivirus humano 2 em um indivíduo, para a detecção de ácido nucleico de pegivirus humano 2 e para a detecção de pegivirus humano 2 em uma amostra, e, composição
CN104262250A (zh) * 2014-09-01 2015-01-07 深圳市美凯特科技有限公司 三碘代甲状腺素半抗原发光标记物及合成方法
ES2828713T3 (es) 2014-10-29 2021-05-27 Abbott Lab Ensayos de detección de anticuerpos anti-VHC objeto usando péptidos de captura NS3
BR112017021256A2 (pt) 2015-04-03 2018-06-26 Abbott Laboratories dispositivos e métodos para a análise de amostras
EP3278108B1 (de) 2015-04-03 2021-03-17 Abbott Laboratories Vorrichtungen und verfahren zur probenanalyse
US20170089905A1 (en) 2015-09-28 2017-03-30 Abbott Japan Co., Ltd. Methods of diagnosing hepatocellular carcinoma and pancreatic cancer
AU2017339809B2 (en) 2016-10-03 2022-02-17 Abbott Laboratories Improved methods of assessing UCH-L1 status in patient samples
CN109863396B (zh) 2016-10-05 2021-11-05 雅培实验室 用于样品分析的装置和方法
WO2018175942A1 (en) 2017-03-23 2018-09-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
BR112019021612A2 (pt) 2017-04-15 2020-05-12 Abbott Laboratories Métodos para auxiliar o diagnóstico hiperagudo e determinação de traumatismo crânioencefálico em um indivíduo humano com o uso de biomarcadores precoces
AU2018256845B2 (en) 2017-04-28 2024-03-14 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
CN110651190A (zh) 2017-05-25 2020-01-03 雅培实验室 用早期生物标记物帮助确定是否对已遭受或可能已遭受头部损伤的人受试者执行成像的方法
BR112019025313A2 (pt) 2017-05-30 2020-06-23 Abbott Laboratories Métodos para auxílio no diagnóstico e avaliação de uma lesão cerebral traumática leve em um indivíduo humano usando troponina cardíaca i
JP7454945B2 (ja) 2017-07-03 2024-03-25 アボット・ラボラトリーズ 血液中のユビキチンカルボキシ末端ヒドロラーゼｌ１レベルを測定するための、改善された方法
EP3661537A4 (de) 2017-08-03 2021-06-09 The Cleveland Clinic Foundation Verbesserte peptidexpression und apo-h-spezifische antikörper-detektion
AU2018378971A1 (en) 2017-12-09 2020-01-02 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase l1 (UCH-L1)
WO2019112860A1 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
WO2019133717A1 (en) 2017-12-29 2019-07-04 Abbott Laboratories Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
US11249091B2 (en) 2018-02-22 2022-02-15 The Cleveland Clinic Foundation Detection of glucuronidated and 3-bromotyrosine
CN112384801A (zh) 2018-05-04 2021-02-19 雅培制药有限公司 用于改进小体积样品的免疫测定灵敏度和动力学的依次采样方法
WO2020180695A1 (en) 2019-03-01 2020-09-10 Abbott Laboratories Methods for predicting major adverse cardiovascular events in subjects with coronary artery disease
CA3175523A1 (en) 2020-04-13 2021-10-21 Antti Virtanen Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
US20220043000A1 (en) 2020-08-04 2022-02-10 Abbott Laboratories Methods and kits for detecting sars-cov-2 protein in a sample
US20220170948A1 (en) 2020-12-01 2022-06-02 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2022147147A1 (en) 2020-12-30 2022-07-07 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
JP2024517728A (ja) 2021-04-29 2024-04-23 アボット・ラボラトリーズ ハイスループット分析用に試料をプールするためのシステム及び方法
WO2022245920A1 (en) 2021-05-18 2022-11-24 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
BR112023026199A2 (pt) 2021-06-14 2024-03-05 Abbott Lab Métodos para diagnosticar ou auxiliar no diagnóstico de lesão cerebral causada por energia acústica, energia eletromagnética, onda de sobrepressurização e/ou rajada de vento
EP4392783A1 (de) 2021-08-27 2024-07-03 Abbott Laboratories Verfahren zum nachweis von immunoglobulin g, subklassen 4 (igg4) in einer biologischen probe
WO2023034777A1 (en) 2021-08-31 2023-03-09 Abbott Laboratories Methods and systems of diagnosing brain injury
WO2023056268A1 (en) 2021-09-30 2023-04-06 Abbott Laboratories Methods and systems of diagnosing brain injury
CA3240822A1 (en) 2021-12-17 2023-06-22 Tony Lee Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
US20230213536A1 (en) 2021-12-28 2023-07-06 Abbott Laboratories Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
WO2024059708A1 (en) 2022-09-15 2024-03-21 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
WO2024107430A1 (en) 2022-11-17 2024-05-23 Regeneron Pharmaceuticals, Inc. Methods for assaying enzyme activity

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3714344A (en) * 1969-05-01 1973-01-30 Mallinckrodt Chemical Works Method for determining thyroxine in blood serum and reagent therefor
US4040907A (en) * 1974-06-20 1977-08-09 Syva Company Iodothyronine enzyme conjugates
NL7605447A (nl) * 1975-06-26 1976-12-28 Byk Mallinckrodt Chem Prod Radioimmunoproefmethode voor de bepaling van thyroxine.
US4307071A (en) * 1977-08-02 1981-12-22 Kallestad Laboratories, Inc. Analytical reagent and method
US4329461A (en) * 1980-01-11 1982-05-11 Syva Company Fluorescent thyroid hormone conjugates and their uses
US4391795A (en) * 1980-03-21 1983-07-05 Becton Dickinson And Company Assay for free thyroid hormone
DE3173632D1 (en) * 1981-09-11 1986-03-13 Amersham Int Plc Derivatives of iodothyronine compounds and their use in an assay for the free iodothyronine compounds
US4668640A (en) * 1981-12-11 1987-05-26 Abbott Laboratories Fluorescence polarization immunoassay utilizing substituted carboxyfluoresceins
US4476229A (en) * 1982-11-08 1984-10-09 Abbott Laboratories Substituted carboxyfluoresceins
US4510251A (en) * 1982-11-08 1985-04-09 Abbott Laboratories Fluorescent polarization assay for ligands using aminomethylfluorescein derivatives as tracers
US4614823A (en) * 1982-11-08 1986-09-30 Abbott Laboratories Aminomethylfluorescein derivatives
US4476228A (en) * 1982-11-08 1984-10-09 Abbott Laboratories Determination of unsaturated thyroxine binding protein sites using fluorescence polarization techniques
US4636478A (en) * 1984-07-16 1987-01-13 Becton, Dickinson And Company Monoclonal antibodies recognizing L-thyroxine
DE3504406A1 (de) * 1985-02-08 1986-08-14 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur bestimmung der bindungskapazitaet des thyroxin bindenden globulins
DE3751673T2 (de) * 1986-10-24 1996-08-01 Abbott Lab Test, Indikatoren, Immunogene und Antikörper für Benzodiazepine
US4912208A (en) * 1987-06-29 1990-03-27 Abbott Laboratories Fluorophores for encapsulation into liposomes
US5145790A (en) * 1990-05-04 1992-09-08 Abbott Laboratories Reagents and method for detecting polychlorinated biphenyls
ES2084069T3 (es) * 1990-08-15 1996-05-01 Abbott Lab Reactivos de inmunoensayo y metodo para la determinacion de ciclosporina.
ATE180018T1 (de) * 1991-08-23 1999-05-15 Molecular Probes Inc Verwendung von haloalkylderivaten von reportermolekülen zur analyse der metabolischen aktivität in zellen
US5296599A (en) * 1991-09-19 1994-03-22 Millipore Corporation Activated carbamates compounds

Also Published As

Publication number Publication date
JP3327551B2 (ja) 2002-09-24
DE69332988T2 (de) 2004-05-19
HK1026264A1 (en) 2000-12-08
EP0649533A4 (de) 1996-08-21
DE69328622D1 (de) 2000-06-15
EP0649533A1 (de) 1995-04-26
US5648272A (en) 1997-07-15
WO1993020442A1 (en) 1993-10-14
US5593896A (en) 1997-01-14
ES2148225T3 (es) 2000-10-16
JPH07505714A (ja) 1995-06-22
CA2131727A1 (en) 1993-10-14
EP0649533B1 (de) 2000-05-10
ES2198823T3 (es) 2004-02-01
DE69332988D1 (de) 2003-06-18

Similar Documents

Publication Publication Date Title
DE69328622D1 (de) Reagenzien und verfahren zum nachweis und zur quantifizierung von thyroxin in flüssigen proben
DE68928157T2 (de) Verfahren und Vorrichtung zur Bestimmung von in einer Flüssigkeitsprobe enthaltenen Teilchen
DE69217197D1 (de) Vorrichtung und verfahren zur verbesserten probenkonzentrierung bei kapillarelektrophorese
DE69308957T2 (de) Verfahren und Vorrichtung zur Handhabung von Proben
DE69329346D1 (de) Vorrichtung und verfahren zur detektion und diskrimination von oberflächenfehlern
DE69841864D1 (de) Testvorrichtung und Verfahren zum Nachweis von Restanalyten in Proben
DE69206136T2 (de) Vorrichtung und Verfahren zur Trennung von Flüssigkeitsproben.
ATA64388A (de) Verbessertes verfahren zum nachweis von nucleinsaeuren und reagenzienkombination und besteck zu seiner durchfuehrung
DE69220714T2 (de) Automatischer Analysenapparat, geeignet zum Lesen von Behälterdaten, und Verfahren zur Handhabung von darin verwendeten Reagenzien
DE3854334T2 (de) Verfahren und Gerät zur Bestimmung von Substanzen.
ATE146600T1 (de) Verfahren und zusammensetzung zum nachweis von chlorid-ionen in flüssigkeiten
DE69614563T2 (de) Verfahren zur quantifizierung von biologischem material in einer probe
DE3886140D1 (de) Gerät und Verfahren zur Verdünnung und Mischung von Flüssigkeitsproben.
DE4490301T1 (de) Vorrichtung und Verfahren zur Entnahme von Materialproben
DE69434254D1 (de) Vorrichtung und verfahren zur flüssigkeitsanalyse
DE69429230D1 (de) Vorrichtung und verfahren zur automatischen prüfung von proben
DE69633496D1 (de) Verfahren und Vorrichtung zur Injektion von flüssigen Proben in einen Gaschromatographen
ATA194096A (de) Vorrichtung und verfahren zur messung der konzentration von stoffen in flüssigkeiten
DE69320053D1 (de) Vorrichtung und verfahren zur identifizierung und quantifizierung von geschichteten substanzen
DE69012598D1 (de) Verfahren und Vorrichtung zur Feststellung von Fehlerstellen in langen metallischen Streifen.
DE59310235D1 (de) Verfahren und Vorrichtung zum optischen Bestimmen von Feststoff-Konzentrationen in Wasser
DE69210434T2 (de) Ein kolorimetrisches Verfahren und Reagenz zum Nachweis von Lithium in einer Testprobe
DE69840725D1 (de) Methode und reagenzien zum bestimmen von substanzen in biologischen proben
DE69408165D1 (de) Ein verfahren zum aufsammeln kleiner probenflüssigkeismengen und probenbehälter dafür
DE68911619D1 (de) Reagenz und verfahren zum nachweis von rheumatoiden faktoren.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition